This paper explores the tension between the provision of accessible health care and health industry development in Korea and Taiwan. Since the late 1990s, Korea and Taiwan have looked to develop their domestic biotechnology sector and health technology industries more generally. Through a mix of public policy reforms in capital markets, upstream science and technology development, intellectual property rights, industrial promotion, education and labor up-skilling, government actors and domestic firms (both start-ups and conglomerates) have attempted to grow domestic health technology industries. With a strong base in technological innovation, pharmaceutical manufacturing and medical care provision, health technology industrial development appears to be promising in both places. To be sure, the universalization of health care provision (through public/private social insurance) in Korea and Taiwan during the late 1980s and into the 1990s effectively means that domestic market size for new medical care products and services is significant. For instance, the purchasing of pharmaceuticals and diagnostic technology accounts for over 25% of each country's total health care expenditures. From industry's perspective, market demand for domestically developed products exists.Yet, this demand-supply relationship is not without friction; indeed, this relationship captures what I see to be the inherent tension between (i) social policy objectives for accessible health care (the 'public health' perspective) and (ii) industrial and economic objectives for health industries development (the 'industrial growth' perspective). As a result, two lines of conflict have begun to emerge in Korea and Taiwan. First, social policymakers interested in containing health care costs for the purposes of maintaining accessible health care provision favor strict price controls over the introduction of new health technologies (pharmaceuticals, diagnostics, medical devices); cost-effectiveness, in this respect, poses a severe demand-side constraint. Health industries, on the other hand, argue that price de-regulation - the lifting of price controls - is absolutely necessary for effective health technology industrial innovation. Second, public health officials in government and progressive civic groups are primarily concerned about the efficacy and safety of new health technologies, particularly among those products and services looking to list as insured benefits in the national health insurance schemes. While firms are also concerned about efficacy and safety issues, they predominantly favor quicker and less stringent regulatory measures for new product approval. In other words, industry seeks streamlined regulation.These two emergent lines of conflict are not trivial when it comes to promoting both population health and economic prosperity. First, they draw attention to the inherent conflict between public health policymakers on the one hand (i.e. MOHW, DOH), and industry and industry promoting government ministries on the other (i.e. MOCIE, MOEA). Second, these lines of conflict underscore the inherent institutional friction - or the lack of institutional complementarity - among both government actors and industry. I contend that this friction is particularly significant in the East Asian context given the stylized characterization of the postwar developmental state as being institutionally coherent and the coordinative partner to industry. Third, the tension between the provision of accessible health and the promotion of health industries points to the need for both health and industrial policymakers, along with firms in the health technology sector, to seek out new modes of coordination, inevitably involving new accommodative strategies and institutional re-configuration... ..PAT.-Unpublished Manuscript [ABSTRACT FROM AUTHOR]